Casein Kinase

CX-5279 is a selective inhibitor of casein kinase 2 (CK2), exhibiting IC50 values of 2.73 nM for nCK2 and 0.91 nM for CK2α. This compound demonstrates variable sensitivity to specific mutations, with altered IC50 values of 13.8 nM, 12.5 nM, and 23.35 nM for mutations at Val66 and Ile174. Although CX-5279 shows limited inhibitory activity against PIM1 (IC50 = 8.52 μM), it has been reported to possess anti-proliferative effects in various cancer cell lines. This reagent is applicable in research focused on pancreatic cancer and leukemia.

CK1δ-IN-6 is a selective inhibitor of Casein Kinase 1δ (CK1δ), targeting a key enzyme involved in cellular signaling pathways. Its inhibition has been linked to potential therapeutic applications in neurodegenerative diseases, particularly Alzheimer's disease. Research utilizing CK1δ-IN-6 can elucidate the role of CK1δ in cellular processes and its contribution to disease progression, making it a valuable tool for uncovering new insights into Alzheimer's pathology.

Tyrphostin AG1112 is a potent inhibitor of casein kinase II (CK II). It demonstrates notable inhibition of the p210bcr-abl tyrosine kinase, with IC50 values of 2 μM for p210bcr-abl, 15 μM for epidermal growth factor receptor (EGFR), and 20 μM for platelet-derived growth factor receptor (PDGFR) in relevant cellular models. This compound is valuable for research investigating cancer signaling pathways and therapeutic interventions targeting kinase activity.

Casein kinase 1δ-IN-31 is a selective inhibitor of casein kinase 1 (CK1), demonstrating potent inhibitory activity against CK1α, CK1δ, and p38α with IC50 values of 196 nM, 17 nM, and 18 nM, respectively. Additionally, this compound inhibits Double Homeobox 4 (DUX4) with an IC50 of 1200 nM. Casein kinase 1δ-IN-31 is primarily utilized in research applications to explore CK1 signaling pathways and their roles in various cellular processes and diseases.

4,5,6,7-Tetrabromo-1H-benzimidazole is a selective inhibitor of casein kinase 2 (CK2), functioning through an ATP-competitive mechanism. This compound has been shown to effectively inhibit CK2 activity, making it a valuable tool for investigating the role of CK2 in various cellular processes. Its primary applications include studies on cell proliferation, apoptosis, and signal transduction pathways. Researchers may utilize this reagent to explore CK2's involvement in cancer and other disease states.

CK1δ-IN-7 is a selective inhibitor of casein kinase 1δ (CK1δ), a crucial mediator in various cellular signaling pathways. This compound exhibits potent inhibition of CK1δ activity, making it a valuable tool for investigating the role of CK1δ in cellular processes such as circadian rhythms, cellular proliferation, and apoptosis. Researchers can utilize CK1δ-IN-7 in studies related to cancer, neurodegenerative diseases, and other pathophysiological conditions linked to CK1δ signaling dysregulation.

CK1δ-IN-8 is a selective inhibitor of casein kinase 1 delta (CK1δ), a crucial regulator in various cellular signaling pathways. This compound demonstrates significant potential in Alzheimer's disease research by modulating phosphorylation processes linked to protein aggregation and neurodegeneration. Its application may aid in elucidating the molecular mechanisms underlying Alzheimer's and developing therapeutic strategies.

Casein kinase 1δ-IN-30 is a selective inhibitor of Casein kinase 1δ (CK1δ). This compound demonstrates significant biological activity in modulating CK1δ activity, making it a valuable tool for investigating neurodegenerative diseases and related pathways. Its application in research can enhance understanding of CK1δ's role in cellular processes and potential therapeutic targets in neurodegeneration.

CK1δ-IN-5 is a selective inhibitor of Casein kinase 1δ (CK1δ), a key enzyme involved in various cellular processes. This compound plays a significant role in the study of neurodegenerative diseases by modulating upstream signaling pathways that may contribute to neuronal dysfunction. Researchers can utilize CK1δ-IN-5 to explore potential therapeutic targets and elucidate the molecular mechanisms underlying these diseases.

CK1-IN-5 is a selective inhibitor of Casein Kinase 1 (CK1). It has been shown to extend the circadian period by inhibiting the activity of AtCKL3 and AtCKL4. This compound is of significant interest in circadian rhythm research and offers potential applications in studies of sleep disorders and metabolic regulation.

SR-2890 is a highly selective ATP-competitive inhibitor of casein kinase 1 delta (CK1δ) and 1 epsilon (CK1ε), exhibiting IC50 values of 4 nM and 44 nM, respectively. This compound effectively inhibits the serine/threonine kinase activity of CK1δ and has demonstrated antiproliferative effects against human A375 melanoma cells. Additionally, SR-2890 has shown potential utility in research related to melanoma and in studying diseases associated with CK1δ/ε, such as Alzheimer's disease, due to its favorable in vivo pharmacokinetic properties and metabolic stability.

Casein kinase 1δ-IN-29 is a potent inhibitor of p38α and casein kinase 1, demonstrating IC50 values of 0.041 µM for p38α, 0.005 µM for CK1δ, and 0.447 µM for CK1ε. This compound effectively interrupts the cell cycle at the subG1 phase and induces apoptosis in AC1-M88 cells. It serves as a valuable tool in research applications focused on cell cycle regulation and apoptosis pathways.

Hsp90-Cdc37-IN-4 is a selective inhibitor of the Hsp90-Cdc37 protein-protein interaction (PPI). This compound disrupts the interaction by inhibiting casein kinase 2 (CK2), leading to reduced phosphorylation of Cdc37 at Serine 13. In cellular assays, Hsp90-Cdc37-IN-4 has been shown to induce G0/G1 cell cycle arrest and activate apoptotic pathways via the mitochondria. Additionally, it exhibits significant anti-breast cancer properties, making it a valuable tool in cancer research.

Orobol is a selective inhibitor of Casein Kinase 1 epsilon (CK1ε) with demonstrated anti-skin-aging and anti-obesity effects. It targets multiple kinases, including VEGFR2, MAP4K5, MNK1, MUSK, TOPK, and TNIK, exhibiting inhibitory activity with IC50 values ranging from 1.24 to 4.45 μM. Additionally, Orobol inhibits various phosphoinositide 3-kinase (PI3K) isoforms, specifically showing activity with IC50 values between 3.46 and 5.27 μM for PI3K α/β/γ/K/δ. These properties make Orobol valuable for investigating signaling pathways related to cellular growth, metabolism, and aging.

ON 108600 is a potent inhibitor of casein kinase 2 (CK2), TYRK1 (DYRK), and TNIK, demonstrating IC50 values of 0.016 μM against DYRK1A, 0.007 μM against DYRK2, 0.05 μM against CK2α1, 0.005 μM against CK2α2, and 0.005 μM against TNIK. This compound exhibits promising antitumor activity, making it a valuable tool for research applications focused on cancer biology, signaling pathways, and kinase inhibition studies. Its specificity for these kinases positions ON 108600 as a critical reagent for investigating therapeutic strategies targeting kinase-related diseases.

CX-5011 free base is a potent inhibitor of casein kinase 2 (CK2), targeting this serine/threonine kinase to modulate cellular signaling pathways. It also serves as a Rac-1 activator, enhancing processes such as methuosis and macropinocytosis. The compound has been shown to induce apoptosis and decrease the phosphorylation of ribosomal protein S6 (rpS6), making it a valuable tool for research applications in cancer biology and cellular metabolism.

5,6-Dichlorobenzimidazole riboside (DRB) functions as a selective inhibitor of several carboxyl-terminal domain kinases, notably casein kinase II and cell cycle-dependent kinases (CDKs). This nucleoside analog exhibits antitumor activity and has been shown to induce apoptosis in targeted cancer cells. Its role in modulating kinase activity makes DRB valuable for research in cancer biology and cell cycle regulation.